Endpoints News

Q&A: Novo research chief Petersen says streamlined R&D speeds discovery
问答:诺和诺德研发主管雅各布•斯滕•彼得森称精简研发加速新药发现

Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early research and work in the clinic.
就在马兹亚尔•迈克•道斯达于2025年夏天出任诺和诺德掌门人之际,该公司表示将重组其研发活动,把负责早期研究和临床开发的团队合并在一起。

本报道最初发表于Endpoints News。请点击这里查看原文

Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early research and work in the clinic.

就在马兹亚尔•迈克•道斯达(Maziar Mike Doustdar)于2025年夏天出任诺和诺德(Novo Nordisk)掌门人之际,该公司表示将重组其研发活动,把负责早期研究和临床开发的团队合并在一起。

您已阅读3%(347字),剩余97%(9892字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归Endpoints News所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×